Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting

AstraZeneca to lower cost of medicines for American patients

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price

Bristol Myers Squibb to present new cardiovascular data at ESC Congress 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion

GlaxoSmithKline Pharmaceuticals appoints Vishwanath Swarup as Commercial Head - General Medicines

Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines

Zydus Lifesciences appoints Vikram Shukla as President - Parenteral Operations

He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS